Search Results for keywords:"importer application"

VHG Labs, doing business as LGC Standards, has applied to the Drug Enforcement Administration (DEA) to register as an importer of specific controlled substances for analytical testing purposes. The DEA has announced this in the Federal Register and is accepting comments or objections from registered bulk manufacturers and other interested parties until February 24, 2025. Requests for a hearing related to this application must also be sent to the DEA by this date. The authorization sought does not include the importation of finished dosage forms approved by the Food and Drug Administration for commercial sale.

LTS Therapy Systems, LLC is seeking to become a registered importer of certain controlled substances for research and development purposes. The Drug Enforcement Administration (DEA) is asking for public comments or objections to this application by April 7, 2025. Comments must be submitted electronically through the Federal eRulemaking Portal. The company is not permitted to import these substances for commercial sale, and any registration approval will align with legal requirements.

VHG Labs, operating as LGC Standards, has submitted an application to the Drug Enforcement Administration (DEA) to become an importer of specific controlled substances, including synthetic cannabidiol and synthetic tetrahydrocannabinol. The company intends to supply these substances to research facilities for drug testing and analysis. Interested parties, such as existing manufacturers or applicants of these substances, can submit comments or request a hearing regarding this application before March 22, 2021. This notice does not permit the import of finished drugs for commercial sale.

The Stepan Company has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances, as per the notice from the Justice Department's DEA. The application is to import these substances to manufacture other controlled substances, but not for commercial sale in finished form. Interested parties, such as current manufacturers or applicants, can comment or request a hearing about this application until April 9, 2025. Comments and hearing requests should be submitted through specified DEA addresses or electronically via the Federal eRulemaking Portal.

Maridose, LLC has applied to the Drug Enforcement Administration (DEA) to become registered as an importer of certain controlled substances. This registration will allow the company to import specific synthetic cannabinoids, like synthetic cannabidiol and synthetic tetrahydrocannabinol, for research and analysis purposes. Public comments or objections regarding this application can be submitted until April 25, 2025, through the Federal eRulemaking Portal. The DEA will only approve the permit if it aligns with the specific business activities authorized under federal law.

Lonza Tampa, LLC has applied to the Drug Enforcement Administration to become registered as an importer of controlled substances, specifically focusing on the drug code 7437 (Psilocybin). They plan to use Psilocybin as a bulk active pharmaceutical ingredient for clinical trials, research, and analytical purposes. The DEA is allowing registered bulk manufacturers or applicants to submit electronic comments or objections to this application by March 20, 2025. Requests for a hearing can also be submitted by this date.

Medi-Physics, Inc., which does business as GE Healthcare, has submitted an application to the Drug Enforcement Administration (DEA) to become an importer of specific controlled substances. The company intends to import small amounts of Ioflupane, which is an analogue of Cocaine, for research and development purposes, as the required form is unavailable in the U.S. Anyone wishing to comment or request a hearing on this application must do so by February 11, 2021. The DEA's approval will depend on compliance with specific regulatory standards.

Vici Health Sciences, LLC has applied to become an importer of specific controlled substances to support their research and clinical trials. The Drug Enforcement Administration (DEA) is accepting public comments and objections to this application until February 27, 2025. Interested parties can submit their comments electronically through the Federal eRulemaking Portal. The DEA has specified that this permit will not authorize the import of finished medication forms for sale.

Pharmaron Manufacturing Services (US) LLC has applied to be registered as an importer of certain controlled substances. The Drug Enforcement Administration (DEA) announced this application and is inviting comments and requests for hearings from other registered bulk manufacturers and applicants until April 25, 2025. The company aims to use the imported substances for analytical purposes and production processes but is not authorized for commercial sale of finished dosage forms. The submission of comments should be done electronically through the Federal eRulemaking Portal.

Myonex Inc has applied for registration as an importer of specific controlled substances, according to a notice from the Drug Enforcement Administration (DEA). The substances are intended for use in clinical trials, research, and analytical purposes, and not for commercial sale of finished dosage forms. Interested parties have until March 29, 2021, to submit written comments or objections, or to request a hearing regarding this application. Written submissions should be directed to the DEA at their office in Springfield, Virginia.